Apr. 2 at 4:23 PM
$CRDL what people missing is how broad CardiolRx really is.
This isn’t just a pericarditis drug. CardiolRx targets cardiac inflammation at the tissue level, a key driver across multiple conditions.
Pericarditis is just the first entry point and already validated. Rilonacept (Arcalyst), an injectable IL-1 inhibitor with higher toxicity, is doing ~
$670M+ revenue and growing toward ~$ 900M in 2026
Yet CardiolRx is oral, safer, and shows signs of disease modification.
MAVERIC-Pilot showed pain↓, CRP↓, recurrence↓. ARCHER then showed LV mass, ECV, ICV normalization, meaning real reversal of inflammation.
That opens expansion into:
• Myocarditis
• Heart failure with inflammation (HFpEF/HFrEF subset)
• Post-viral cardiac inflammation
• General inflammatory cardiomyopathies
This is what big pharma wants:
• Proven market (pericarditis)
• Pipeline in one molecule
• Scalable + safer profile
Pericarditis is just the start. DYOR.
